| Record ID | marc_university_of_toronto/uoft.marc:5584104094:1292 |
| Source | University of Toronto |
| Download Link | /show-records/marc_university_of_toronto/uoft.marc:5584104094:1292?format=raw |
LEADER: 01292cam 22003254a 4500
001 1164306
005 20061021052618.0
008 030115s2002 onca bt f000 0 eng
020 $a9781894620574
020 $a1894620577
041 09 $aeng
042 $apcc
044 $9Canada
060 00 $a2003 A-561
060 10 $aWK 825$bE27 2002
245 00 $aEfficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents :$bsystematic review and budget impact analysis /$cMichel Boucher ... [et al.].
260 $aOttawa :$bCanadian Coordinating Office for Health Technology Assessment,$c[2002]
300 $ax, 76 p. :$bill.
490 1 $aTechnology report ;$vissue 29
500 $a"October 2002."
504 $aIncludes bibliographical references (p. 52-57).
650 12 $aDiabetes Mellitus$xdrug therapy
650 12 $aHypoglycemic Agents$xtherapeutic use
650 22 $aCost-Benefit Analysis
655 2 $aEvaluation Studies
655 2 $aTechnical Report
700 1 $aBoucher, Michel,$cB Pharm.
710 2 $aCanadian Coordinating Office for Health Technology Assessment.
830 0 $aTechnology report (Canadian Coordinating Office for Health Technology Assessment) ;$vissue 29.
949 $aWK810 .E27 2002$wNLM$c1$i92011038$lSTACKS$mSUNNYBROOK$rY$sY$tBOOK$u31/10/2007